Compare CRAI & ALVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRAI | ALVO |
|---|---|---|
| Founded | 1965 | 2013 |
| Country | United States | Luxembourg |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.0B |
| IPO Year | 1998 | 2021 |
| Metric | CRAI | ALVO |
|---|---|---|
| Price | $165.22 | $6.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $245.00 | $8.00 |
| AVG Volume (30 Days) | 89.6K | ★ 981.5K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 1.48% | N/A |
| EPS Growth | ★ 20.77 | N/A |
| EPS | ★ 8.14 | N/A |
| Revenue | ★ $751,583,000.00 | N/A |
| Revenue This Year | $7.82 | $13.28 |
| Revenue Next Year | $5.14 | $18.63 |
| P/E Ratio | $19.91 | ★ $18.20 |
| Revenue Growth | ★ 9.33 | N/A |
| 52 Week Low | $132.17 | $2.94 |
| 52 Week High | $227.29 | $9.05 |
| Indicator | CRAI | ALVO |
|---|---|---|
| Relative Strength Index (RSI) | 44.75 | 73.77 |
| Support Level | $152.37 | $3.10 |
| Resistance Level | $166.99 | N/A |
| Average True Range (ATR) | 5.22 | 0.27 |
| MACD | -0.30 | 0.02 |
| Stochastic Oscillator | 46.90 | 95.83 |
CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.
Alvotech is a biopharmaceutical company focused solely on the development and manufacture of biosimilar medicines for patients globally. Its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases. The company's commercialized products incldue AVT02, AVT03, AVT04, AVT05, and AVT06. Its pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, and cancer. Geographically, the company generates the majority of revenue from Europe, and the rest from the USA and the rest of the world.